

Press Releases

All Years

[Advanced Search](#)

MAR 18, 2019

[Perrigo Announces Tentative FDA Approval For The Generic Version Of Finacea® Foam, 15%](#)

MAR 5, 2019

[Perrigo Confirms Patent Challenge for Generic Version of Nascobal®](#)

FEB 27, 2019

[Perrigo Company plc Reports Fourth Quarter And Full-Year 2018 Financial Results](#)

FEB 25, 2019

[Perrigo Receives Leave To Judicially Review Irish Revenue Tax Assessment](#)

- Committed to vigorously challenge the Notice of Amended Assessment; believes it is without merit and incorrect as a matter of law

FEB 14, 2019

[Perrigo Announces Quarterly Dividend](#)

FEB 13, 2019

[Perrigo Announces Patent Litigation Settlement for the Generic Version](#)

[Perrigo Announces Patent Litigation Settlement for the Generic version of Jublia® Topical Solution 10%](#)

FEB 13, 2019

[Perrigo Company plc To Release Fourth Quarter And Calendar Year 2018 Results On February 27, 2019](#)

FEB 6, 2019

[Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Zovirax® Cream 5%](#)

JAN 29, 2019

[Perrigo To Receive Milestone Payment Of \\$250 Million From RPI Finance Trust](#)

JAN 14, 2019

[Perrigo Appoints James Dillard To Role Of Chief Scientific Officer](#)

Show per page

[«](#) [1](#) [...](#) [19](#) [20](#) [21](#) [22](#) [23](#) [24](#) [25](#) [...](#) [95](#) [»](#)



<https://investor.perrigo.com/press-releases?l=10&o=210>